Enríquez-Vega ME, Muñoz-Paredes JG, Cossío-Zazueta A, Ontiveros-Carlos Y, Pacheco-Pittaluga E, Bizueto-Rosas H

Language: Spanish
References: 19
Page: 38-42
PDF size: 243.94 Kb.

ABSTRACT

Introduction: Among the U.S. population, the p81L SDHD (11q23) gene mutation is present in 6-36% of patients with sporadic carotid body tumor (CBT), but in familial cases is high as 80%. That is why the P81L mutation is used as a screening method for carotid body tumor in the U.S. Methods: We included 25 patients who underwent resection of a CBT from January 2010 to June 2015. After informed consent, a blood sample was taken for genetic testing on real-time polymerase chain reaction, in order to identify p81L mutation in the SDHD gene. The information was analyzed with descriptive statistics, using central tendency and description measures. Results: In our group, 92% were females, a mean age of 55.5 years, and 52% were Shamblin type II. The most common place of residence was Mexico City, 8% of the patients had family history, about 20% of the patients had a contralateral tumor and 16% had antecedent of another kind of tumor, 4 (16%) p81L SDHD gene mutations were detected, all of them were heterozygous. Conclusions: The p81L mutation in the SDHD gene was found in the Mexican population in higher grade that in the U.S. population, which explain the high incidence of this pathology in our country, but we need more studies about this subject.

REFERENCES

1. Shamblin WR, ReMine WH, Sheps SG, Harrison EG. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg.1971;122:732-9.

2. Glenn MM, Virendra IP. Carotid Artery. Carotid body tumors and other disorders. En: Cronenwett J, Johnston W, editores. Rutherford’s Vascular surgery. 8th ed. Philadelphia: Elsevier; 2014. p. 1598-614.

3. Rodríguez CS, López GJ, Labastida AS. Carotid body tumors in inhabitants of altitudes higher than 2000 meters above sea level. Head Neck. 1998;20:374-8.

4. Pellitteri PK, Rinaldo A, Myssiorek D, Gary JC, Bradley PJ, Devaney KO, et al. Paragangliomas of the head and neck. Oral Oncol. 2004;40:563-75.

5. Balcazar A, López C, Soto I. Tumor del cuerpo carotídeo de altura. Revisión de 35 años. Conceptos actuales, manejo de 333 tumores y nueva clasificación. Técnicas endovasculares. 2011;XIV:3927-39.

6. Torres PF, Gómez AF, Guzmán PC, Mendoza PJ, Labastida AS. Carotid body tumor. Analysis of 96 cases. Rev Invest Clin. 1991;43:119-23.

7. Luna OK, Rascon OM, Villavicencio VV, Herrera GA. Does Shamblin’s classification predict postoperative morbidity in carotid body tumors? A proposal to modify Shamblin’s classification. Eur Arch Otorhinolaryngol. 2006;263:171-5.

8. Persky MS, Setton A, Niimi Y, Hartman J, Frank D, Berenstein A. Combined endovascular and surgical treatment of head and neck paragangliomas a team approach. Head Neck. 2002;24:423-31.

9. Martínez C, Sánchez B, Arriola H, Laven R, Bacelis R. Paragangliomas carotídeo, yugulares y aórticos. Experiencia de 25 años. Angiologia. 2005;33(4);110-3.

10. Luna K, Rascon M, Villavicencio V, Granados G, Herrera G. Carotid body tumors: review of a 20-year experience. Oral Oncology. 2005;41:56-61.

11. Baysal BE. Hereditary paraganglioma targets diverse paraganglioma. J Med Genet. 2002;39:617-22.

12. Fishbein L, Nathanson K. Pheochromocytoma and paraganglioma understanding the complexities of genetic background. Cancer Genetics. 2012;201:1-11.

13. Sevilla MA, Hermsen MA, Weiss MM, Grimbergen A, Balbín M, Llorente JL, et al. Chromosomal changes in sporadic and familial head and neck paragangliomas. Otolaryngol Head Neck Surg. 2009;140:724-9.

14. Mhatre AN, Li Y, Feng L, Gasperin A, Lalwan AK. SDHB, SDHC and SDHD mutation screen in sporadic and familial head and neck paragangliomas. Clin Genet. 2004;66;461-6.

15. Bikhazi PH, Messina L, Mhatre AN, Goldstein JA, Lalwani AK. Molecular pathogenesis in sporadic head and neck paraganglioma. Laryngoscope. 2000;110:1346-8.

16. Taschner PE, Jansen JC, Baysal BE, Bosch A, Rosenberg EH, Bröcker- Vriends AH, et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer. 2001;31:274-81.

17. Eng C, Kiuru M, Fernández A, Lauri A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer. 2003;3:193-202.

18. Boehm CD. Use of polymerase chain reaction for diagnosis of inherited disorders. Clin Chem. 1989;35:1843-8.

19. Fruhmann J, Geigl JB, Konstantiniuk P, Cohnert TU. Paraganglioma of the carotid body: treatment strategy and SDH-gene mutations. Eur J Vasc Endovasc Surg. 2013;45:431-6.